TACC3 and breast cancer: Compared to canonical FGFR3 mutations, BC cell lines harboring FGFR3-TACC3 fusions are much more sensitive to FGFR inhibitors than those with FGFR3 mutation, likely due to ligand-independent dimerization and constitutive activation of oncogenic signaling [16, 17].